Rose Merc Limited Completes Equity Warrant Allotment and Major Corporate Restructuring

2 min read     Updated on 25 Mar 2026, 02:35 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Rose Merc Limited successfully concluded its March 24, 2026 board meeting with major corporate developments including completion of equity warrant allotment worth ₹3.20 crores to 13 investors, strategic appointment of Vikas Phadnis as advisor, subsidiary restructuring with two companies transitioning to associate status, and acquisition of 48% stake in organic healthcare company Abaca Care Private Limited.

powered bylight_fuzz_icon
35380077

*this image is generated using AI for illustrative purposes only.

Rose Merc Limited has successfully completed its board meeting held on March 24, 2026, announcing significant corporate developments including the allotment of equity warrants, subsidiary status changes, and strategic appointments. The board meeting, which commenced at 4:00 PM and concluded at 5:45 PM, addressed multiple key agenda items in compliance with SEBI regulations.

Equity Warrant Allotment Completed

The company has successfully allotted 3,55,723 equity warrants convertible into equity shares on a preferential basis for cash. This follows the in-principal approval granted by BSE vide letter no. LOD/PREF/DA/FIP/1859/2025-26 dated March 11, 2026.

Parameter: Details
Total Warrants Allotted: 3,55,723
Issue Price per Warrant: ₹90.00 (including premium of ₹80.00)
Total Consideration: ₹3,20,15,070.00
Amount Received (25%): ₹80,03,767.50
Conversion Period: 18 months from allotment date

Warrant Allottee Distribution

The warrants have been allocated among 13 investors across promoter and non-promoter categories. The largest individual allocation went to Tanveersingh Ahuja with 1,11,000 warrants, followed by Amitkumar Yogendra Singh and Niti Trivedi with 55,556 warrants each.

Allottee Name: Category Warrants Allotted
Tanveersingh Ahuja: Non-Promoter 1,11,000
Amitkumar Yogendra Singh: Non-Promoter 55,556
Niti Trivedi: Non-Promoter 55,556
Vikas Kamlakar Phadnis: Non-Promoter 50,000
Vedika Thakur: Non-Promoter 40,000
Vijay Acharya: Non-Promoter 30,000
Kirti Chunilal Savla: Promoter 11,111
Others (6 investors): Non-Promoter 2,250
Total: Both Categories 3,55,723

Subsidiary Status Changes

The board approved significant changes in subsidiary holdings, resulting in two companies transitioning from subsidiary to associate status:

Rahi Pakhle RM Private Limited: Following director resignation from the board, the company's status changed to associate. The entity contributed ₹75,000 in revenue (0.009% of total) and had a net worth of ₹58,330 (0.017% of total).

Kaale and Rose Merc Advisors Private Limited: The board approved the sale of 49% equity stake for ₹49,000, along with director resignation, changing its status to associate company. The entity generated ₹5,70,000 in revenue (0.072% of total) with a negative net worth of ₹1,65,612.06.

Company: Revenue Net Worth Status Change
Rahi Pakhle RM Pvt Ltd: ₹75,000 (0.009%) ₹58,330 (0.017%) Subsidiary to Associate
Kaale and Rose Merc Advisors: ₹5,70,000 (0.072%) -₹1,65,612.06 (-0.049%) Subsidiary to Associate

Strategic Appointments and New Acquisition

The board appointed Mr. Vikas Phadnis as Advisor-Strategy and Growth. Phadnis brings extensive experience as co-founder of Lighthouse Learning Group and has successfully built education enterprises over two decades.

Additionally, the company completed its investment in Abaca Care Private Limited, acquiring a 48% stake for ₹48,000. The target company operates in the organic healthcare sector, developing homeopathy pain relief products, and was incorporated on May 17, 2023.

Investment Details: Specifications
Target Company: Abaca Care Private Limited
Stake Acquired: 48%
Investment Amount: ₹48,000
Industry: Organic healthcare
Status: Now subsidiary of Rose Merc
Incorporation Date: May 17, 2023

The comprehensive board meeting outcome reflects Rose Merc Limited's strategic focus on capital raising through warrant allotment while optimizing its subsidiary portfolio and strengthening advisory capabilities for future growth initiatives.

Historical Stock Returns for Rose Merc

1 Day5 Days1 Month6 Months1 Year5 Years
-0.19%+0.36%+0.13%+4.44%+55.40%+1,778.23%

What strategic initiatives will Rose Merc pursue with the ₹3.2 crore raised through warrant allotment, and how might this impact their market positioning?

How will the conversion of equity warrants over the next 18 months affect Rose Merc's shareholding structure and potential dilution for existing shareholders?

What synergies does Rose Merc expect to achieve through its 48% acquisition of Abaca Care in the organic healthcare sector?

Rose Merc Limited Grants 10 Lakh Stock Options Under Employee Stock Option Plan 2024

2 min read     Updated on 25 Mar 2026, 01:53 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Rose Merc Limited granted 10,00,000 stock options to one eligible employee under RML ESOP 2024 on March 24, 2026, with an exercise price of ₹72 per option. The options vest after one year and can be exercised within four years of vesting, with each option convertible to one equity share of ₹10 face value. The SEBI-compliant plan includes provisions for various employment scenarios and corporate actions, with resulting shares ranking pari-passu with existing equity shares.

powered bylight_fuzz_icon
35929422

*this image is generated using AI for illustrative purposes only.

Rose merc Limited has announced the grant of employee stock options under its newly established RML Employee Stock Option Plan 2024. The company's Compensation Committee approved this significant employee incentive initiative during its meeting held on March 24, 2026, demonstrating the organization's commitment to employee retention and motivation through equity participation.

Stock Option Grant Details

The Compensation Committee has granted a substantial allocation of stock options to enhance employee engagement and align interests with company performance. The grant represents a focused approach to employee compensation, targeting specific personnel for equity participation.

Parameter: Details
Total Options Granted: 10,00,000 (Ten Lakhs)
Number of Recipients: 1 (One) Eligible Employee
Face Value per Share: ₹10
Exercise Price: ₹72 per Option
Plan Name: RML Employee Stock Option Plan 2024

Vesting and Exercise Framework

The stock options operate under a structured timeline designed to encourage long-term employee commitment. Each stock option entitles the holder to apply for one fully paid-up equity share of the company.

Aspect: Terms
Vesting Period: 1 (One) year from grant date
Exercise Window: 4 (Four) years from vesting date
Exercise Method: Wholly or partly during exercise window
Share Conversion: One option converts to one equity share

Regulatory Compliance and Key Features

The RML ESOP 2024 has been structured in accordance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, ensuring full regulatory compliance. The plan includes comprehensive provisions for various employment scenarios and corporate actions.

Key features of the employee stock option plan include:

  • Administration by the company's Compensation Committee
  • Specific provisions for handling options in cases of death, permanent incapacity, resignation, termination, and retirement
  • Automatic adjustments for corporate actions such as rights issues, bonus issues, stock splits, mergers, or reorganizations
  • No lock-in restrictions on equity shares allotted upon option exercise
  • Pari-passu ranking with existing equity shares from allotment date

Corporate Governance and Documentation

The grant was formally communicated to BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Managing Director Vaishali Parkar Kumar signed the disclosure documents, ensuring proper corporate governance protocols were followed.

The comprehensive disclosure includes detailed terms and conditions, pricing formulas, and procedural guidelines for option exercise. Currently, no options have been exercised, and no money has been realized from option exercises, as the grants are newly issued and subject to the one-year vesting period.

Historical Stock Returns for Rose Merc

1 Day5 Days1 Month6 Months1 Year5 Years
-0.19%+0.36%+0.13%+4.44%+55.40%+1,778.23%

Will Rose Merc expand the ESOP program to include more employees if this initial grant proves successful in retention and performance?

How might the ₹72 exercise price compare to Rose Merc's expected share price when the options vest in March 2027?

What specific performance metrics or milestones is Rose Merc targeting that justify granting such a large option pool to a single employee?

More News on Rose Merc

1 Year Returns:+55.40%